Lofexidine
Active ingredient: Lofexidine Hydrochloride
In short: Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
What is Lofexidine used for?
Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Lofexidine dosage
The usual Lofexidine tablet starting dosage is three 0.18 mg tablets taken orally 4 times daily during the period of peak withdrawal symptoms (generally the first 5 to 7 days following last use of opioid) with dosing guided by symptoms and side effects. There should be 5 to 6 hours between each dose. The total daily dosage of Lofexidine tablets should not exceed 2.88 mg (16 tablets) and no single dose should exceed 0.72 mg (4 tablets).
Lofexidine tablet treatment may be continued for up to 14 days with dosing guided by symptoms.
Discontinue Lofexidine tablets with a gradual dose reduction over a 2- to 4-day period to mitigate Lofexidine tablet withdrawal symptoms (e.g., reducing by 1 tablet per dose every 1 to 2 days). .The Lofexidine tablet dose should be reduced, held, or discontinued for individuals who demonstrate a greater sensitivity to lofexidine tablets side effects . Lower doses may be appropriate as opioid withdrawal symptoms wane.
Lofexidine tablets can be administered in the presence or absence of food.
Recommended dosage adjustments based on the degree of hepatic impairment are shown in Table 1. .
Table 1: Dosage Recommendations in Patients with Hepatic Impairment
Mild
Impairment | Moderate
Impairment | Severe
Impairment
Child-Pugh score | 5-6 | 7-9 | > 9
Recommended dose | 3 tablets 4 times daily (2.16 mg per day) | 2 tablets 4 times daily(1.44 mg per day) | 1 tablet 4 times daily (0.72 mg per day)
Recommended dosage adjustments based on the degree of renal impairment are shown in Table 2. Lofexidine tablets may be administered without regard to the timing of dialysis .
Table 2: Dosage Recommendations in Patients with Renal Impairment
Moderate Impairment | Severe Impairment, End-Stage Renal Disease, or on Dialysis
Estimated GFR, mL/min/1.73 m2 | 30-89.9 | < 30
Recommended dose | 2 tablets4 times daily(1.44 mg per day) | 1 tablet4 times daily(0.72 mg per day)
How to take Lofexidine — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information).
Lofexidine tablets may mitigate, but not completely prevent, the symptoms associated with opioid withdrawal syndrome, which may include feeling sick, stomach cramps, muscle spasms or twitching, feeling of cold, heart pounding, muscular tension, aches and pains, yawning, runny eyes and sleep problems (insomnia). Patients should be advised that withdrawal will not be easy. Additional supportive measures should be clearly advised, as needed.
Hypotension and Bradycardia
Inform patients to be alert for any symptoms of low blood pressure or pulse (e.g., dizziness, lightheadedness, or feelings of faintness at rest or upon abruptly standing). Advise patients on how to reduce the risk of serious consequences should hypotension occur (sit or lie down, carefully rise from a sitting or lying position). …
Warnings & precautions
Do not take this medicine if: None.
Lofexidine tablets can cause a decrease in blood pressure, a decrease in pulse, and syncope . Monitor vital signs before dosing. Monitor symptoms related to bradycardia and orthostasis.
Patients being given Lofexidine tablets in an outpatient setting should be capable of and instructed on self-monitoring for hypotension, orthostasis, bradycardia, and associated symptoms. If clinically significant or symptomatic hypotension and/or bradycardia occur, the next dose of lofexidine tablet should be reduced in amount, delayed, or skipped.
Inform patients that Lofexidine tablets may cause hypotension and that patients moving from a supine to an upright position may be at increased risk for hypotension and orthostatic effects. Instruct patients to stay hydrated, on how to recognize symptoms of low blood pressure, and on how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position). Instruct outpatients to withhold Lofexidine tablets doses when experiencing symptoms of hypotension or bradycardia and to contact their health care provider for guidance on how to adjust dosing.
Avoid using Lofexidine tablets in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, chronic renal failure, and in patients with marked bradycardia.
Avoid using Lofexidine tablets in combination with medications that decrease pulse or blood pressure to avoid the risk of excessive bradycardia and hypotension.
Lofexidine tablets prolong the QT interval. Avoid using lofexidine tablet in patients with congenital long QT syndrome. Monitor ECG in patients with congestive heart failure, bradyarrhythmias, hepatic impairment, renal impairment, or patients taking other medicinal products that lead to QT prolongation (e.g. methadone). …
Lofexidine side effects
The following serious adverse reactions are described elsewhere in labeling: • Hypotension, Bradycardia, and Syncope
• QT Prolongation
• Central Nervous System Depression
• Opioid Overdose
• Discontinuation Symptoms
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to adverse reaction rates observed for another drug and may not reflect the rates observed in practice.
The safety of Lofexidine tablets was supported by three randomized, double-blind, placebo-controlled clinical trials, an open-label study, and clinical pharmacology studies with concomitant administration of either methadone, buprenorphine, or naltrexone.
The three randomized, double-blind, placebo-controlled clinical trials enrolled 935 subjects dependent on short-acting opioids undergoing abrupt opioid withdrawal. Patients were monitored before each dose in an inpatient setting.
Table 3 presents the incidence, rounded to the nearest percent, of adverse events that occurred in at least 10% of subjects treated with Lofexidine tablets and for which the incidence in patients treated with Lofexidine tablets were greater than the incidence in subjects treated with placebo in a study that tested two doses of Lofexidine tablets, 2.16 mg per day and 2.88 mg per day, and placebo. The overall safety profile in the combined dataset was similar. …
Drug interactions
Lofexidine tablets and methadone both prolong the QT interval. ECG monitoring is recommended in patients receiving methadone and Lofexidine tablets concomitantly .
Coadministration of Lofexidine tablets and oral naltrexone resulted in statistically significant differences in the steady-state pharmacokinetics of naltrexone. It is possible that oral naltrexone efficacy may be reduced if used concomitantly within 2 hours of Lofexidine tablets. This interaction is not expected if naltrexone is administered by non-oral routes .
Lofexidine tablets potentiate the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. Advise patients to inform their healthcare provider of other medications they are taking, including alcohol .
Coadministration of Lofexidine tablets and paroxetine resulted in a 28% increase in the extent of absorption of Lofexidine. Monitor for orthostatic hypotension and bradycardia when an inhibitor of CYP2D6 is used concomitantly with Lofexidine tablets .
About this medicine
Lofexidine tablets contain lofexidine, a central alpha-2 adrenergic agonist, as the hydrochloride salt. Lofexidine hydrochloride is chemically designated as 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5 dihydro-1H- imidazole monohydrochloride with a molecular formula of C11H12Cl2N2O•HCl. Its molecular weight is 295.6 g/mole and its structural formula is:
Lofexidine hydrochloride is a white to off-white crystalline powder freely soluble in water, methanol, and ethanol. It is slightly soluble in chloroform and practically insoluble in n-hexane and benzene.
Lofexidine tablets are available as round, concave-shaped, peach-colored, film-coated tablets, debossed with “C” on one side and “71” on other side for oral administration. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ce4488e2-842c-45ba-aca7-075a900e2a1c. Read the full official label on DailyMed.